GHIT Fund

GHIT Fund secures commitments of over US$200 million to its replenishment for the acceleration of Japanese innovation for infectious diseases of the developing world

This announcement demonstrates the continued leadership and commitment of the Government of Japan, leading life sciences companies, international foundations and other partners to combat neglected diseases; with this replenishment, which marks a doubling of previous commitments, GHIT will accelerate and expand its development of new tools while ensuring they are accessible and delivered to the world’s most vulnerable.

Read More →

GHIT Fund announces new investments

Approach shows promise for achieving malaria eradication and tackling rapidly spreading malaria drug resistance; GHIT also announces investments in malaria and tuberculosis diagnostics and new treatments for leishmaniasis and soil-transmitted helminthiasis.

Read More →

Japanese fund awards $12 million to develop innovative tools for Chagas disease, schistosomiasis, parasitic roundworms and TB

TOKYO, JAPAN (March 20, 2014)—The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms. GHIT also announced a second round of funding of US$5.65 million for a novel vaccine candidate for tuberculosis and unveiled a new investment program that will help researchers find the most promising new drug candidates to battle these and other infectious diseases.

Read More →

Japanese fund moves quickly to invest in promising technology against malaria, tuberculosis and chagas disease

The Global Health Innovation and Technology Fund (GHIT Fund) announced that it will invest US$720,000 for early work on a novel vaccine candidate against TB being co-developed by Japan’s Create Vaccine Co., Ltd. and Aeras. The announcement is part of the first round of grants by GHIT Fund, a public-private partnership launched earlier this year that brings together the Japanese Government, the Bill & Melinda Gates Foundation and pharmaceutical companies.  

Read More →

Page 1 of 1 · Total posts: 4

1